{"nctId":"NCT01690988","briefTitle":"The Prevention of Delirium and Complications Associated With Surgical Treatments Multi Center Clinical Trial","startDateStruct":{"date":"2014-02-01","type":"ACTUAL"},"conditions":["Delirium"],"count":746,"armGroups":[{"label":"Ketamine (0.5 mg/kg)","type":"EXPERIMENTAL","interventionNames":["Drug: Ketamine (0.5 mg/kg)"]},{"label":"Normal saline (placebo)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Normal Saline (placebo)"]},{"label":"Ketamine (1 mg/kg)","type":"EXPERIMENTAL","interventionNames":["Drug: Ketamine (1 mg/kg)"]}],"interventions":[{"name":"Ketamine (0.5 mg/kg)","otherNames":["Ketalar"]},{"name":"Normal Saline (placebo)","otherNames":["Normal saline"]},{"name":"Ketamine (1 mg/kg)","otherNames":["Ketalar"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients 60 and older\n* Competent to provide informed consent\n* Undergoing major surgery (e.g., open cardiac surgery, open or thoracoscopic thoracic surgery, abdominal surgery, open urological surgery, open gynecological surgery, major orthopedic surgery, major vascular surgery including endovascular procedures, major ear, nose and throat surgery).\n\nExclusion Criteria:\n\n* Patients with an allergy to ketamine\n* Those in whom a significant elevation of blood pressure would constitute a serious hazard (e.g., pheochromocytoma, aortic dissection)\n* Unable to provide informed consent\n* Patients with drug misuse history (e.g., ketamine, cocaine, heroin, amphetamine, methamphetamine, MDMA, phencyclidine, lysergic acid, mescaline, psilocybin)\n* Patients taking anti-psychotic medications (e.g., chlorpromazine, clozapine, olanzapine, risperidone, haloperidol, quetiapine, risperidone, paliperidone, amisulpride, sertindole)\n* Patients with a weight outside the range 50 kg - 200 kg (110 lbs - 440 lbs)","healthyVolunteers":false,"sex":"ALL","minimumAge":"60 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients With Incidence of Delirium Across All Patients at Baseline and Over Post-operative Days 1-3","description":"According to Confusion Assessment Method or Confusion Assessment Method for Intensive Care Unit criteria the number of patients that had any positive CAM on any day for all patients. The main effect evaluated will be to determine whether ketamine decreases delirium, table 3 of the protocol provides a useful guide for the potential findings of the current study with their implications.\n\nTo further clarify, delirium will be assessed on the day of surgery, when possible and on the subsequent three days POD 1-3, as long as as patients remain in the hospital and are assessable (i.e., not sedated to a RASS \\<-3). The assessments on POD 1-3 will be done twice daily, once in the morning and once in the afternoon. The primary outcome of the study includes only the delirium incidence on POD 1-3.\n\nThe primary comparison will be between the combined ketamine groups and the placebo group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]}]},{"type":"SECONDARY","title":"Daily Maximum Pain Recorded","description":"Assessed by observer-based Behavioral Pain Scale or Behavioral Pain Scale (Non-Intubated) with subsequent administration of patient-reported Visual Analog Scale The behavioral pain scale has three domains and ranges from 3 to 15. The visual analog scale is a continuous scale from 0 to 100 mm. Daily Maximum Pain accounted for pain level in the AM or PM for both the VAS and the BPS/BPS-NI a higher value means a worse outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"63.5","spread":null},{"groupId":"OG002","value":"68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"59","spread":null},{"groupId":"OG002","value":"57.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"52.5","spread":null},{"groupId":"OG002","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Opioid Consumption","description":"Assessed from patients' medical charts. All morphine equivalent drugs consumed by patients perioperatively\n\nOpioid Drugs included:\n\n\\* Postoperatively while still in hospital, the list of pain medication used included Morphine, Hydromorphone, Meperidine, Nalbuphine, Oxycodone,Oxymorphone, Tramadol, bupivacaine, (Codeine, Fentanyl, Naloxone) Total Opiates (Morphine Equivalent) in milligrams The median(IQR) opioid consumption was compared across the three study groups Placebo vs. Lo-K (0.5 mg/kg) vs. Hi-K (1 mg/kg)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.9","spread":null},{"groupId":"OG001","value":"94.7","spread":null},{"groupId":"OG002","value":"78.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Postoperative Nausea and Vomiting","description":"Assessed from patient-reported postoperative nausea and vomiting section of Behavioral Pain Scale or Behavioral Pain Scale (Non-Intubated) Patients where asked whether they \"currently have nausea/vomiting\" AM \\& PM the response choices: None, Mild, Moderate, Severe Incidence of nausea\\\\vomiting accounted for any positive reporting(Mild, moderate, or sever) Daily incidence accounted for any positive incidence AM/PM in each POD Any POD nausea/vomiting reports the incidence across day 1-3\n\nThe incidence of nausea and or vomiting was compared across the three study groups Placebo vs. Lo-K (0.5 mg/kg) vs. Hi-K (1 mg/kg) for POD 1-3 and overall.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG001","value":"73","spread":null},{"groupId":"OG002","value":"64","spread":null}]}]}]},{"type":"SECONDARY","title":"ICU and/or Hospital Length of Stay","description":"Assessed from patients' medical charts","classes":[]},{"type":"SECONDARY","title":"Adverse Outcomes (Number of Patients With Hallucinations)","description":"Assessed via Confusion Assessment Method or Confusion Assessment Method for Intensive Care Unit","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"62","spread":null}]}]}]},{"type":"SECONDARY","title":"Adverse Outcomes (Number of Patients With Nightmares)","description":"Assessed via Confusion Assessment Method or Confusion Assessment Method for Intensive care Unit","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"34","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":227},"commonTop":["Atrial Fibriliation","Anaemia/Bleeding","Infection","Renal","Hypotension"]}}}